Effect of Breast Milk on Diaper Dermatitis in Infants
dermatit
Study of the Effect of Breast Milk and Hamamelis Virginiana (Potency12MG/100G) on the Healing of Diaper Dermatitis in Infants
1 other identifier
interventional
30
1 country
2
Brief Summary
Diaper dermatitis, one of infants' most common health problems, can be treated with various methods. One of these methods is breast milk. Studies show that breast milk is a non-harmful, accessible and effective product in the healing of dermatitis. This study was planned to be a randomized, controlled, and single-blinded study to evaluate the effect of breast milk and diaper rash cream containing Hamamelis virginiana (potency 12mg/100g) 5.35 g/100g on the healing process in 0-12-month-old infants with diaper dermatitis. The population of the study consisted of 0-12 months old infants with diaper dermatitis who applied to the Pediatrics Outpatient Clinic of X Hospital. Since not all infants with diaper dermatitis complaints were examined, the number of the population cannot be known. The sample size was calculated as 26 for each group and 52 in total . 30 infants were planned to be included in each group. The licensed IBM SPSS 22.0 (Statistical Package for the Social Sciences) package program will be used for statistical data analysis. Standard deviation, number and percentage will be used in data analysis. Man Whitney U test and Fisher exact test (repeated measures) will be used to evaluate whether there is a difference between independent groups. For the significance level of the data, 0.05 will be used.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started May 2023
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2023
CompletedFirst Submitted
Initial submission to the registry
December 25, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 18, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
May 10, 2024
CompletedFirst Posted
Study publicly available on registry
November 21, 2024
CompletedMarch 11, 2025
March 1, 2025
9 months
December 25, 2023
March 10, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
It will be evaluated whether there is a difference between breast milk and dermatitis cream in terms of healing diaper dermatitis in babies aged 0-12 months.
Data will be collected using the baby identification form and the Infant Uncomplicated Diaper Dermatitis Severity Rating Scale (UCDAS).
6 months
Study Arms (1)
Uncomplicated Diaper Dermatitis Severity Assessment Scale in Babies
EXPERIMENTALIn the study, a data collection form consisting of 13 questions regarding the sociodemographic characteristics of 0-12 month old babies and the "Uncomplicated Diaper Dermatitis Severity Assessment Scale in Babies, developed by Buckley et al. in 2016 and whose Turkish validity and reliability studies were conducted by Keskin, will be used.
Interventions
In diaper dermatitis care, it was planned to use their mothers' milk for the babies in the experimental group and diaper rash cream containing Hamamelis virginiana (potency 12mg/100g) 5.35 g/100g for the babies in the control group. The reason why diaper rash cream containing Hamamelis virginiana (potency 12mg/100g) 5.35 g/100 g is preferred is that it is the most frequently used cream in cases of uncomplicated diaper dermatitis. The mothers of the babies in the control group will be asked to wash and dry the baby's diaper with soap and water during each diaper change and then apply diaper rash cream containing Hamamelis virginiana (potency 12mg/100g) 5.35 g/100 g. Mothers will be asked to record any new signs and symptoms that develop during the treatment and to inform the investigators will be asked to provide information. Positive and negative effects of treatment will also be recorded.
Eligibility Criteria
You may qualify if:
- Babies fed with breast milk,
- Healthy babies aged 0-6 months,
- Babies who do not have diarrhea or thrush at the time of application,
- Fungus, eczema, allergic disease, etc.Babies without a history of skin disease,
- Babies who do not use antimycotic drugs (Ampotericin etc.), antibiotics and steriods ---before and during the application,
- Babies who do not apply medication or other materials (barrier creams, powder and other medications) to the dermatitis area.
You may not qualify if:
- Babies who are not breastfed
- Those who did not agree to participate in the study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Sakarya Training and Research Hospital
Sakarya, Adapzarı, 54100, Turkey (Türkiye)
Sakarya Üniversitesi
Sakarya, Adapzarı, 54100, Turkey (Türkiye)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Döndü 1 Sevimli Güler, PhD
Sakarya Training and Research Hospital
- STUDY DIRECTOR
Zekiye 4 Turan, PhD
Sakarya University
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SEQUENTIAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 25, 2023
First Posted
November 21, 2024
Study Start
May 1, 2023
Primary Completion
January 18, 2024
Study Completion
May 10, 2024
Last Updated
March 11, 2025
Record last verified: 2025-03
Data Sharing
- IPD Sharing
- Will not share
Our study findings have not yet been published.